• D-Luciferin Sodium Salt: Firefly Luciferase Substrate in Onc

  2026-04-30

  D-Luciferin sodium salt is a highly soluble firefly luciferase substrate enabling sensitive, ATP-dependent bioluminescence imaging in oncology and metabolic research. Its validated performance supports non-invasive monitoring of cell viability and gene expression. APExBIO’s B8311 formulation is widely deployed for robust, reproducible readouts in advanced bioluminescent assays.

• SIRT1/2 Inhibition Unlocks CNS Repair: Cambinol in Translati

  2026-04-30

  This thought-leadership article bridges the mechanistic insights of SIRT1/2-regulated lactylation in CNS injury with strategic experimental guidance. Drawing on recent advances in astrocyte polarization and tumor models, it details how SIRT1/2 Inhibitor IV (cambinol) from APExBIO enables translational researchers to dissect epigenetic-metabolic crosstalk and unlock novel therapeutic strategies.

• Trichostatin A (TSA): Enhancing Epigenetic Cancer Workflows

  2026-04-29

  Trichostatin A (TSA) from APExBIO delivers nanomolar potency and reproducibility for epigenetic regulation in cancer research. This article demystifies TSA’s applied workflows, advanced use-cases, and troubleshooting tips, ensuring bench-to-data confidence in both routine and cutting-edge assays.

• L1023 Anti-Cancer Compound Library: Precision in Drug Discov

  2026-04-29

  Harness the DiscoveryProbe™ L1023 Anti-Cancer Compound Library for high-throughput screening and pathway-targeted drug discovery in oncology. This resource bridges advanced biomarker research with actionable therapeutic leads, ensuring robust workflows and reproducible results.

• First-Line Small Cell Lung Cancer: Topotecan, Etoposide & PE

  2026-04-28

  This article examines the reference study on topotecan's role in first-line small cell lung cancer (SCLC) therapy, focusing on its innovation versus established cisplatin/etoposide (PE) regimens. Key findings highlight efficacy, toxicity profiles, and implications for protocol optimization in cancer chemotherapy research.

• Biotin-XX Tyramide Reagent: Precision Cell Surface Labeling

  2026-04-28

  Biotin-XX Tyramide Reagent empowers researchers to achieve ultra-sensitive and selective cell surface protein labeling in tyramide signal amplification workflows. Its unique membrane-impermeant design unlocks high-fidelity proximity labeling and immunohistochemistry signal amplification, as demonstrated in landmark neuroproteomics studies. Discover advanced protocol optimizations and troubleshooting strategies to maximize your assay’s impact.

• Intraperitoneal mRNA-LNP CAR Macrophages for Solid Tumor Imm

  2026-04-27

  Gu et al. (2025) introduce a macrophage-targeted mRNA lipid nanoparticle approach to program chimeric antigen receptor (CAR) macrophages in situ, addressing the challenge of peritoneal metastasis in solid tumors. This study systematically evaluates CAR intracellular domains, demonstrates robust immune activation, and reveals mechanistic insights into tumor microenvironment remodeling.

• Proteoform-Specific Drug Targeting in Native Signaling Envir

  2026-04-27

  This study pioneers the direct characterization of proteoform-specific interactions in native membrane environments using advanced native top-down mass spectrometry. By revealing how post-translational modifications affect protein–ligand and off-target drug interactions, it sets a new benchmark for precision drug development and the design of safer therapeutics targeting complex signaling proteins.

• Protein A/G Magnetic Beads: Streamlined Protein Interaction

  2026-04-26

  Protein A/G Magnetic Beads from APExBIO deliver high-yield, low-background immunoprecipitation workflows for demanding protein interaction and chromatin studies. Their dual recombinant design ensures robust antibody capture with minimal non-specific binding, enabling reproducible results even in complex biological samples.

• TRIM21 Drives ERK1/2 Activation and Drug Resistance in Pitui

  2026-04-25

  This study identifies TRIM21 as a key oncogenic factor in pituitary adenomas, promoting cell proliferation and resistance to dopamine agonists through ERK1/2 ubiquitination and phosphorylation. The research further demonstrates that Quisinostat, a potent HDAC inhibitor, can downregulate TRIM21, offering a potential new therapeutic approach for drug-resistant pituitary tumors.

• Benzyl-Activated Streptavidin Magnetic Beads: Precision in B

  2026-04-24

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) streamline isolation of biotinylated targets with unmatched specificity and workflow versatility. Their low background and robust affinity empower advanced immunoprecipitation, protein interaction studies, and high-throughput drug screening applications.

• 3X (DYKDDDDK) Peptide: Optimizing Affinity Purification Work

  2026-04-24

  The 3X (DYKDDDDK) Peptide empowers researchers with triple-epitope sensitivity, driving high-yield affinity purification and metal-sensitive immunodetection. Discover key workflow enhancements, troubleshooting insights, and advanced applications that position this APExBIO product at the forefront of recombinant protein science.

• RITA (NSC 652287): Precision Oncology Through Quantitative A

  2026-04-23

  Explore how RITA (NSC 652287) empowers high-fidelity anti-cancer research by integrating nuanced in vitro drug response metrics and quantitative assay design. This article uncovers new assay strategies and data interpretation insights for tumor biology.

• Translating Mitochondrial Stress Insights: New Frontiers in

  2026-04-23

  This thought-leadership article bridges mechanistic breakthroughs in mitochondrial stress and ribosome-associated quality control (RQC) with practical, protocol-driven strategies for apoptosis detection. By spotlighting the One-step TUNEL Cy3 Apoptosis Detection Kit from APExBIO, we provide translational researchers with actionable guidance for dissecting DNA fragmentation in complex cellular contexts—moving beyond conventional workflows and illuminating emergent therapeutic paradigms.

• Guideline-Based Approaches to Cutaneous Candidiasis and Imid

  2026-04-22

  The referenced guideline provides a comprehensive, evidence-based framework for diagnosing and treating mucocutaneous candidiasis, emphasizing the central role of imidazole antifungals—such as Neticonazole Hydrochloride—in topical therapy. Its findings shape current clinical and laboratory standards for fungal infection management, with implications for research on antifungal mechanisms and cross-domain oncology workflows.

14641 records 1/977 page Next 12345 下5页 Last page